At Mana.bio, we are on a journey to unlock nucleic acid delivery using our AI platform designed to create targeted lipid nanoparticles.
We aim to bring solutions for a wide array of unmet needs to patients, and we believe the best way is through collaborations with companies and researchers that bring their expertise and are willing to partner. If you develop a nucleic acid-based therapeutic payload like mRNA, CRISPR, DNA, etc, and can potentially benefit from Mana.bio’s platform for delivery solutions, let us know.
Our partnerships entail
Licensing out our AI-designed delivery technologies to optimize partners’ nucleic acid payloads.
Co-development of novel delivery solutions, tailored to the partner’s needs.
As the field rapidly evolves, the need for tailored delivery systems that unlock therapeutic opportunities increases. Our AI-driven approach already accelerates development and can advance your nucleic acid-based therapies.